Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Deferred Tax (2016 - 2021)

Enanta Pharmaceuticals' Long-Term Deferred Tax history spans 8 years, with the latest figure at $345000.0 for Q2 2021.

  • For Q2 2021, Long-Term Deferred Tax fell 97.74% year-over-year to $345000.0; the TTM value through Jun 2021 reached $345000.0, down 97.74%, while the annual FY2020 figure was $345000.0, 96.96% down from the prior year.
  • Long-Term Deferred Tax reached $345000.0 in Q2 2021 per ENTA's latest filing, roughly flat from $345000.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $17.7 million in Q2 2017 to a low of $345000.0 in Q3 2020.
  • Average Long-Term Deferred Tax over 5 years is $8.5 million, with a median of $9.2 million recorded in 2018.
  • Peak YoY movement for Long-Term Deferred Tax: surged 203.32% in 2017, then plummeted 97.74% in 2021.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $7.6 million in 2017, then increased by 22.2% to $9.2 million in 2018, then rose by 15.22% to $10.7 million in 2019, then tumbled by 96.76% to $345000.0 in 2020, then changed by 0.0% to $345000.0 in 2021.
  • Per Business Quant, the three most recent readings for ENTA's Long-Term Deferred Tax are $345000.0 (Q2 2021), $345000.0 (Q1 2021), and $345000.0 (Q4 2020).